These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 1872272)

  • 1. Ridogrel in the setting of percutaneous transluminal coronary angioplasty.
    Timmermans C; Vrolix M; Vanhaecke J; Stammen F; Piessens J; Vercammen E; De Geest H
    Am J Cardiol; 1991 Aug; 68(5):463-6. PubMed ID: 1872272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ridogrel as an adjunct to thrombolysis in acute myocardial infarction.
    van der Wieken LR; Simoons ML; Laarman GJ; Van den Brand M; Nijssen KM; Dellborg M; Hermens W; Vrolik W
    Int J Cardiol; 1995 Nov; 52(2):125-34. PubMed ID: 8749872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus Aspirin Patency Trial (RAPT).
    Circulation; 1994 Feb; 89(2):588-95. PubMed ID: 8313547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thromboxane A2 receptor antagonism and synthase inhibition in essential hypertension.
    Ritter JM; Barrow SE; Doktor HS; Stratton PD; Edwards JS; Henry JA; Gould S
    Hypertension; 1993 Aug; 22(2):197-203. PubMed ID: 8340155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of a combined administration of ridogrel and ketanserin in patients with intermittent claudication.
    De Cree J; Geukens H; Gutwirth P; De Clerck F; Vercammen E; Verhaegen H
    Int Angiol; 1993 Mar; 12(1):59-68. PubMed ID: 8376914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ridogrel inhibits systemic and renal formation of thromboxane A2 and antagonizes platelet thromboxane A2/prostaglandin endoperoxide receptors upon chronic administration to man.
    Weber C; Beetens JR; Tegtmeier F; Van Rooy P; Vercammen E; Wouters L; De Clerck F
    Thromb Haemost; 1992 Aug; 68(2):214-20. PubMed ID: 1412169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of ridogrel, a thromboxane synthase inhibitor and receptor antagonist, on blood pressure in the spontaneously hypertensive rat.
    Quest DW; Wilson TW
    Jpn J Pharmacol; 1998 Dec; 78(4):479-86. PubMed ID: 9920205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of ridogrel on the prostacyclin-thromboxane ratio in nulliparous third trimester-pregnant rhesus monkeys.
    Keith JC; Goodrich JA; Endo Y; Taub D; Mehlman P; Ward G
    Prostaglandins; 1993 Jun; 45(6):547-55. PubMed ID: 8337414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ridogrel improves maternal/fetal homeostasis in an ovine model of pregnancy-induced hypertension.
    Keith JC; Endo Y; Warwick K; Keith KE; Brugh S; Rowles TK
    Prostaglandins; 1994 Mar; 47(3):247-63. PubMed ID: 8016393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined thromboxane A2 synthase inhibition and prostaglandin endoperoxide receptor antagonism limits myocardial infarct size after mechanical coronary occlusion and reperfusion at doses enhancing coronary thrombolysis by streptokinase.
    Vandeplassche G; Hermans C; Somers Y; Van de Werf F; de Clerck F
    J Am Coll Cardiol; 1993 Apr; 21(5):1269-79. PubMed ID: 8459087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ridogrel does not increase the speed and rate of coronary recanalization in patients with myocardial infarction treated with alteplase and heparin.
    Tranchesi B; Pileggi F; Vercammen E; Van de Werf F; Verstraete M
    Eur Heart J; 1994 May; 15(5):660-4. PubMed ID: 8056007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Placental transfer of the thromboxane synthetase inhibitor ridogrel in the late-pregnant ewe.
    Schneider TJ; Struijk PC; Wallenburg HC
    Eur J Obstet Gynecol Reprod Biol; 1999 Sep; 86(1):83-7. PubMed ID: 10471147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimal heparinization in coronary angioplasty--how much heparin is really warranted?
    Kaluski E; Krakover R; Cotter G; Hendler A; Zyssman I; Milovanov O; Blatt A; Zimmerman E; Goldstein E; Nahman V; Vered Z
    Am J Cardiol; 2000 Apr; 85(8):953-6. PubMed ID: 10760333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty.
    Schwartz L; Bourassa MG; Lespérance J; Aldridge HE; Kazim F; Salvatori VA; Henderson M; Bonan R; David PR
    N Engl J Med; 1988 Jun; 318(26):1714-9. PubMed ID: 2967433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thromboxane A2 accounts for bronchoconstriction but not for platelet sequestration and microvascular albumin exchanges induced by fMLP in the guinea pig lung.
    Bureau MF; De Clerck F; Lefort J; Arreto CD; Vargaftig BB
    J Pharmacol Exp Ther; 1992 Feb; 260(2):832-40. PubMed ID: 1738127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ridogrel, a combined thromboxane synthase inhibitor and receptor blocker, decreases elevated plasma beta-thromboglobulin levels in patients with documented peripheral arterial disease.
    Hoet B; Arnout J; Van Geet C; Deckmyn H; Verhaeghe R; Vermylen J
    Thromb Haemost; 1990 Aug; 64(1):87-90. PubMed ID: 2148849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of low dose heparin in elective coronary angioplasty.
    Koch KT; Piek JJ; de Winter RJ; David GK; Mulder K; Tijssen JG; Lie KI
    Heart; 1997 Jun; 77(6):517-22. PubMed ID: 9227294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ridogrel enemas in distal ulcerative colitis.
    Auwerda JJ; Zijlstra FJ; Tak CJ; van den Ingh HF; Wilson JH; Ouwendijk RJ
    Eur J Gastroenterol Hepatol; 2001 Apr; 13(4):397-400. PubMed ID: 11338069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aspirin, but not heparin, suppresses the transient increase in thromboxane biosynthesis associated with cardiac catheterization or coronary angioplasty.
    Ciabattoni G; Ujang S; Sritara P; Andreotti F; Davies G; Simonetti BM; Patrono C; Maseri A
    J Am Coll Cardiol; 1993 May; 21(6):1377-81. PubMed ID: 8473644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Failure of percutaneous transluminal coronary angioplasty to stimulate platelet and prostaglandin activity.
    Stine RA; Magorien RD; Bush CA; Kolibash AJ; Leier CV; Fertel RH; Brandt J; Unverferth DV
    Cathet Cardiovasc Diagn; 1985; 11(3):247-54. PubMed ID: 3160477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.